Neue Catecholamin-Prodrugs zur Verwendung bei der Behandlung von Morbus Parkinson

Details

Veröffentlichungs-Nr.

EP4748440

Anmeldetag

23. November 2018

Veröffentlichung

27. Mai 2026

Rechtsraum

EP

IPC

A61P25/00

Abstract

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id)whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i);wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

Anmelder

Firma

H. Lundbeck A/S

Land

🇩🇰 Dänemark